Small caps round-up: James Cropper, ValiRx, ReNeuron
James Cropper, a specialist paper and materials group, has said that pre-execptional profit before tax is set to be in line with market expectations. The company also said its previously announced restructuring process will reduce the size of the UK workforce by eight per cent during the current year and is expected to result in cost savings of around one million pounds each year. The firm added that it will be necessary to make a provision of 0.8m pounds in the financial statement for redundancy payments.
James Cropper, a specialist paper and materials group, has said that pre-execptional profit before tax is set to be in line with market expectations. The company also said its previously announced restructuring process will reduce the size of the UK workforce by eight per cent during the current year and is expected to result in cost savings of around one million pounds each year. The firm added that it will be necessary to make a provision of 0.8m pounds in the financial statement for redundancy payments.
ValiRx, the AIM-listed life sciences firm, has boasted a 157% rise in revenue for 2011, up from £0.177m to £0.455m following a 'signficant' capital injection. During the period the company was in receipt of $1.1m, the procees of the sale of its subsidiary diagnostic development business.
Start your trial of MoneyWeek today
Get unparalleled financial insight, analysis and expert opinion you can profit from.
Sign up for MoneyWeek’s free twice-daily newsletter.
Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.
Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.
